POTENZA, ALESSIA
 Distribuzione geografica
Continente #
AS - Asia 229
EU - Europa 197
NA - Nord America 102
SA - Sud America 13
AF - Africa 6
OC - Oceania 2
Totale 549
Nazione #
US - Stati Uniti d'America 101
HK - Hong Kong 94
RU - Federazione Russa 72
IT - Italia 49
SG - Singapore 48
VN - Vietnam 31
DE - Germania 27
CN - Cina 24
ID - Indonesia 12
BR - Brasile 11
CH - Svizzera 11
KR - Corea 11
IE - Irlanda 8
SE - Svezia 8
NL - Olanda 7
JP - Giappone 4
AT - Austria 3
FI - Finlandia 3
UA - Ucraina 3
AU - Australia 2
ES - Italia 2
FR - Francia 2
GB - Regno Unito 2
GH - Ghana 2
IN - India 2
PE - Perù 2
ZA - Sudafrica 2
BD - Bangladesh 1
CA - Canada 1
EG - Egitto 1
GE - Georgia 1
MA - Marocco 1
TR - Turchia 1
Totale 549
Città #
Hong Kong 91
Singapore 24
Hefei 18
Fairfield 15
Milan 12
Hanoi 11
Munich 11
Seoul 11
Moscow 10
Ho Chi Minh City 9
Dublin 8
Jakarta 8
Nuremberg 7
Zurich 7
Ashburn 6
Cambridge 5
Frankfurt am Main 5
Cagliari 4
Princeton 4
Tokyo 4
Wilmington 4
Chicago 3
Ferrara 3
Houston 3
Santa Clara 3
Shanghai 3
Woodbridge 3
Accra 2
Acquafredda 2
Andover 2
Ann Arbor 2
Azzano San Paolo 2
Biên Hòa 2
Brescia 2
Brisbane 2
Lappeenranta 2
Las Vegas 2
Lima 2
Mantova 2
Modena 2
Montecchio Maggiore 2
New York 2
Phoenix 2
Seattle 2
Vienna 2
Amsterdam 1
Araras 1
Basel 1
Beijing 1
Belo Horizonte 1
Berlin 1
Betim 1
Bologna 1
Brooklyn 1
Bình Dương Province 1
Cesano Boscone 1
Charleston 1
Ciampino 1
Columbus 1
Congonhal 1
Corridonia 1
Falls Church 1
Fes 1
Geneva 1
Greensboro 1
Guangzhou 1
Haiphong 1
Itupeva 1
Johannesburg 1
Kent 1
Lawrence 1
Los Angeles 1
Lübeck 1
Maceió 1
Maricá 1
Monza 1
Nashville 1
Norwalk 1
Oberentfelden 1
Osnago 1
Presidente Prudente 1
Quận Bình Thạnh 1
Quận Bảy 1
Quận Mười 1
Quận Năm 1
Rome 1
Sorocaba 1
St Louis 1
São Bernardo do Campo 1
Tanta 1
Tbilisi 1
Toulouse 1
Turku 1
Tân Tiến 1
Vancouver 1
Vila Velha 1
Vinh 1
Vũng Tàu 1
Totale 381
Nome #
Effector T cells co-expressing PD1 and CD39 are enriched in colorectal tumors: implications for cancer immunotherapy 138
TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals 92
CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function 47
Epithelial ovarian cancer is infiltrated by activated effector T cells co-expressing CD39, PD-1, TIM-3, CD137 and interacting with cancer cells and myeloid cells 42
Correction to: Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B (Nature Immunology, (2022), 23, 9, (1379-1392), 10.1038/s41590-022-01290-3) 42
Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells 39
Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B 37
Harnessing the tumor microenvironment to boost adoptive T cell therapy with engineered lymphocytes for solid tumors 34
Workflow for high-dimensional flow cytometry analysis of T cells from tumor metastases 32
Harnessing T cell exhaustion and trogocytosis to isolate patient-derived tumor-specific TCR 32
TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells 29
Flow cytometry data mining by cytoChain identifies determinants of exhaustion and stemness in TCR-engineered T cells 25
Totale 589
Categoria #
all - tutte 2.310
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.310


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202147 0 0 0 0 0 0 26 5 8 2 3 3
2021/202212 0 2 2 2 0 1 0 0 1 0 0 4
2022/202320 5 5 2 0 0 4 0 0 0 0 2 2
2023/202442 0 0 0 0 11 2 6 7 4 4 3 5
2024/2025461 8 11 6 10 4 48 44 32 39 88 46 125
2025/20267 7 0 0 0 0 0 0 0 0 0 0 0
Totale 589